ライフサイエンスコーパス: combination chemotherapy

1 egarding the safety and patient tolerance of combination chemotherapy.

2 ategy B was fluorouracil until failure, then combination chemotherapy.

3 gents, doublets, triplets, and multiple drug combination chemotherapy.

4 ersus FU; and gemcitabine versus gemcitabine combination chemotherapy.

5 sed after they received cisplatin-containing combination chemotherapy.

6 of highly active antiretroviral therapy and combination chemotherapy.

7 RECIST responses were in patients receiving combination chemotherapy.

8 ssociated with poor response to conventional combination chemotherapy.

9 nts had a superior outcome when treated with combination chemotherapy.

10 ntrolled trials assessing fluorouracil-based combination chemotherapy.

11 yeloid leukemia (AML) is anthracycline-based combination chemotherapy.

12 h conventional-dose cisplatin-and-ifosfamide combination chemotherapy.

13 nical presentation and is more refractory to combination chemotherapy.

14 Acute toxic effects were more common with combination chemotherapy.

15 ed FL3 who received anthracycline-containing combination chemotherapy.

16 deliverable nanomedicines for more effective combination chemotherapy.

17 radiation therapy followed by six cycles of combination chemotherapy.

18 trials will explore rhuMAb VEGF alone and in combination chemotherapy.

19 re refractory to fludarabine at the start of combination chemotherapy.

20 ncer received four to six cycles of standard combination chemotherapy.

21 e form of LGL leukemia that was resistant to combination chemotherapy.

22 from adjuvant treatment with cisplatin-based combination chemotherapy.

23 of the fourth and final course of cisplatin combination chemotherapy.

24 nts treated with adjuvant fluorouracil-based combination chemotherapy.

25 an important agent to consider for trials of combination chemotherapy.

26 outine cures of human testicular tumors with combination chemotherapy.

27 sis, can serve as a model to further analyze combination chemotherapy.

28 olds promise for optimization of anti-cancer combination chemotherapy.

29 er patients who cannot tolerate conventional combination chemotherapy.

30 s (P < .001); 89% of these patients received combination chemotherapy.

31 further research on multidrug resistance and combination chemotherapy.

32 readily AQ resistance will be selected with combination chemotherapy.

33 est greater efficacy in treating tumors with combination chemotherapies.

34 ar and Hydrea, for antisense therapy, and in combination chemotherapies.

35 n over 80% of patients using cisplatin-based combination chemotherapy [1].

36 Standard (non-antimetabolite) combination chemotherapy administered past the first tri

37 re immediate versus deferred cisplatin-based combination chemotherapy after radical cystectomy in pat

38 mechanisms of resistance and optimize future combination chemotherapy against MM.

39 Combination chemotherapy alone including gemcitabine, a

40 CVAD combination chemotherapy alone or with the chemosensitiz

41 pursue to avoid this complication is to use combination chemotherapy alone, especially in young wome

42 sitive, with a high overall response rate to combination chemotherapy and a minority of complete resp

43 Clinicians should offer combination chemotherapy and an HER2-targeted agent as i

44 s the majority of afflicted patients despite combination chemotherapy and hematopoietic cell transpla

45 tic interactions resulting from simultaneous combination chemotherapy and highly active antiretrovira

46 Three studies used a cisplatin-containing combination chemotherapy and included primarily patients

47 sive treatment with anthracycline-containing combination chemotherapy and involved-field radiation th

48 adolescents with Hodgkin's disease includes combination chemotherapy and low-dose involved-field rad

49 wed similar response rates to platinum-based combination chemotherapy and no difference in overall su

50 hod (TITE-CRM) for dose-escalation trials of combination chemotherapy and radiation.

51 Even with combination chemotherapy and radiotherapy treatments, th

52 rwent extrapleural pneumonectomy followed by combination chemotherapy and radiotherapy.

53 abine after progression after both cisplatin combination chemotherapy and subsequent high-dose chemot

54 Initial therapy included combination chemotherapy and surgery.

55 Eight had progressed after intensive combination chemotherapy and three after allogeneic or a

56 ad received first-line taxane/platinum-based combination chemotherapy and were platinum refractory or

57 treated as primary therapy responded to the combination chemotherapy and were preserved.

58 ith GCT who progressed after cisplatin-based combination chemotherapy and were subsequently treated w

59 We advocate earlier inclusion of combinations +/- chemotherapy and of newly diagnosed pat

60 agnosed in 1995, 40% received tamoxifen, 16% combination chemotherapy, and 7% both, an increase from

61 isk of graft rejection, anti-CD20 treatment, combination chemotherapy, and administration of EBV-spec

62 Multisystem disease should be treated with combination chemotherapy, and current experimental thera

63 ciated with unfavorable responses to empiric combination chemotherapy, and defining robust subtypes w

64 if they were treated for lymphoma, received combination chemotherapy, and did not develop therapy-re

65 Single agent is preferable to combination chemotherapy, and longer planned duration im

66 ggest a broader perspective on the design of combination chemotherapy approaches with immediate clini

67 ng considerations for the modern practice of combination chemotherapy are also discussed.

68 itial treatment: Three patients who received combination chemotherapy are currently alive and free of

69 Studies involving combination chemotherapy are ongoing, and preliminary re

70 dvanced NSCLC and PS 2 are best treated with combination chemotherapy as first-line therapy.

71 with radiation therapy, and 46 also received combination chemotherapy as part of their initial treatm

72 d-risk patients of trial AIEOP-BFM ALL 2000 (Combination Chemotherapy Based on Risk of Relapse in Tre

73 ication of systemic therapy with neoadjuvant combination chemotherapy before standard treatment is fe

74 He was successfully treated with combination chemotherapy but unfortunately died, 6 month

75 d with similar response rates as neoadjuvant combination chemotherapy but with significantly lower to

76 contrasting approaches: a single agent, and combination chemotherapy capable of curing diffuse aggre

77 tic infections were examined with the use of combination chemotherapy combined with HAART.

78 mized controlled phase III trial of adjuvant combination chemotherapy compared gemcitabine and capeci

79 Survival was improved after gemcitabine combination chemotherapy compared with gemcitabine alone

80 (95% CI, 0.38 to 0.67) with cisplatin-based combination chemotherapy compared with hydroxyurea.

81 authors introduce the innovative concept of combination chemotherapy consisting of 2 antimetabolites

82 Patients were treated with combination chemotherapy consisting of cyclophosphamide,

83 ith a single-alkylating agent nor aggressive combination chemotherapy cures advanced stage low-grade

84 FU-based combination chemotherapy did not result in better overal

85 whom clonal Ig DNA remained detectable after combination chemotherapy died with lymphoma.

86 resentation, and three patients who received combination chemotherapy died within 5 months of present

87 patients received a median of four cycles of combination chemotherapy during pregnancy.

88 tment has not advanced beyond platinum-based combination chemotherapy, during the past 30 years.

89 apy, similarly failed to show monotherapy or combination chemotherapy efficacy in a model of postsurg

90 ) intravenous), followed by three courses of combination chemotherapy (either cyclophosphamide, doxor

91 ical series to be investigated in single and combination chemotherapies, especially targeting hematol

92 hese spheroids were then dosed with a common combination chemotherapy, FOLFIRI (folinic acid, 5-fluor

93 cT2-T4a N0M0) is neoadjuvant cisplatin-based combination chemotherapy followed by radical cystectomy.

94 ree cycles of anthracycline-cyclophosphamide combination chemotherapy followed by three cycles of tax

95 Several docetaxel-based combination chemotherapies for hormone refractory prosta

96 The role of combination chemotherapy for advanced bladder cancer con

97 We present our experience with the use of combination chemotherapy for breast cancer during pregna

98 amethasone (dex), are a central component of combination chemotherapy for childhood B-cell precursor

99 ed risk of second tumors after sequential or combination chemotherapy for GTT.

100 rone, Oncovin, Velban, and Prednisone (NOVP) combination chemotherapy for Hodgkin's disease increases

101 improved by the addition of immunotherapy to combination chemotherapy for initial treatment in all su

102 g-term complications of intensive rotational combination chemotherapy for late hematologic relapse (m

103 We conclude that patients treated with PI combination chemotherapy for LR or HR WT or clear cell s

104 up of 6.2 years on (1) the role of intensive combination chemotherapy for older patients with AML, (2

105 Among the women who received platinum-based combination chemotherapy for ovarian cancer, the relativ

106 ative value of increasing ifosfamide dose in combination chemotherapy for patients with soft tissue s

107 and safety of irinotecan and gemcitabine as combination chemotherapy for previously untreated patien

108 Platinum-based combination chemotherapy for PS-2 patients with NSCLC is

109 e) in patients receiving 5 days of cisplatin combination chemotherapy for testicular cancer.

110 se of existing compounds, either alone or in combination chemotherapy, for improved efficacy and safe

111 Strategy C was combination chemotherapy from the outset.

112 supportive care; fluorouracil (FU) versus FU combination chemotherapy; gemcitabine versus FU; and gem

113 Performance status 2 patients treated with combination chemotherapy had a better survival rate than

114 Recently, vinorelbine and cisplatin combination chemotherapy has been shown for the first ti

115 Since the 1960s, combination chemotherapy has been widely utilized as a s

116 The response of liver metastases to systemic combination chemotherapy has improved, but the 2-year su

117 Whereas cisplatin-paclitaxel combination chemotherapy has shown significant efficacy

118 t trial suggests that carboplatin/ifosfamide combination chemotherapy has substantial antitumor activ

119 upplant single radioisotope therapy, much as combination chemotherapy has substantially replaced sing

120 Combination chemotherapies have been a mainstay in the t

121 ttempts to add molecular-targeted therapy to combination chemotherapy have failed except for bevacizu

122 Therapeutic outcomes of combination chemotherapy have not significantly advanced

123 he addition of thoracic radiation therapy to combination chemotherapy improved both complete response

124 Combination chemotherapy improves response rate and fail

125 to assess the penetration and metabolism of combination chemotherapies in three-dimensional colon ca

126 eceived antenatal therapy (doxorubicin based combination chemotherapy in 20 of 24 patients), and 12 d

127 markers of survival for 5-FU and oxaliplatin combination chemotherapy in 5-FU-resistant metastatic co

128 urvival were longer among those who received combination chemotherapy in addition to radiation therap

129 gent before initiating therapy with standard combination chemotherapy in metastatic breast cancer pat

130 gylated-liposomal doxorubicin, with standard combination chemotherapy in patients with advanced AIDS-

131 effectiveness of bevacizumab and nonplatinum combination chemotherapy in patients with recurrent, per

132 The addition of bevacizumab to combination chemotherapy in patients with recurrent, per

133 rmed chemosensitive with the introduction of combination chemotherapy in the 1970s.

134 s to define the contribution of docetaxel to combination chemotherapy in the outcome of patients with

135 This supports the use of gemcitabine-based combination chemotherapy in the treatment of advanced pa

136 of several trials have evaluated the use of combination chemotherapy in this difficult subgroup of p

137 er investigation of gemcitabine-based RT and combination chemotherapy in this disease.

138 This trial (NSABP B-38; Combination Chemotherapy in Treating Women Who Have Unde

139 could be combined with traditional forms of combination chemotherapy in which two or more compounds

140 association between the incidence of DVT and combination chemotherapy including doxorubicin (P =.02)

141 We discuss bladder preserving approaches, combination chemotherapy including new agents, targeted

142 Combination chemotherapy, including the recently develop

143 We propose a strategy of combination chemotherapy incorporating the use of multip

144 this study, the addition of immunotherapy to combination chemotherapy increased toxicity but did not

145 Combination chemotherapy is a useful approach for patien

146 Combination chemotherapy is an important protocol in gli

147 d testicular germ cell tumors with cisplatin combination chemotherapy is based on risk stratification

148 Combination chemotherapy is commonly used to treat advan

149 Cisplatin-based combination chemotherapy is considered standard first-li

150 n in stage II disease, and oxaliplatin-based combination chemotherapy is now routinely used for stage

151 Single-agent or combination chemotherapy is often indicated for such pat

152 oma, and further evaluation of this agent in combination chemotherapy is warranted.

153 ole for combined modality therapy, including combination chemotherapy, is being explored.

154 Front-line platinum-based combination chemotherapy leads to high response rates bu

155 The potential benefit of adding rituximab to combination chemotherapy may be offset by infectious com

156 Recent evidence suggests combination chemotherapy may help some patients, althoug

157 Dose-dense (DD) regimens of combination chemotherapy may produce superior clinical o

158 Nevertheless, rituximab and combination chemotherapy may transiently clear PB or BM

159 pite being initially responsive to intensive combination chemotherapy, most patients relapse and succ

160 Thus, combination chemotherapy must be optimized to increase t

161 Compared with combination chemotherapy, NET as monotherapy with aromat

162 us, stage IV CRC who receive up-front modern combination chemotherapy never require palliative surger

163 Glucocorticoids are extensively used in combination chemotherapy of advanced prostate cancer (PC

164 The combination chemotherapy of FFG was well tolerated and m

165 The effects of combination chemotherapy of HDAC inhibitors and anthracy

166 offer our best hope for treatment-shortening combination chemotherapy of TB.

167 omic profiling to examine the effects of the combination chemotherapy on the colon cancer cells.

168 sease had relapsed or progressed after prior combination chemotherapy or anthracycline therapy.

169 to receive either standard conventional-dose combination chemotherapy or high-dose therapy and an aut

170 cal excision for localized disease; surgery, combination chemotherapy, or prednisone for multicentric

171 roach of surgical cytoreduction and adjuvant combination chemotherapy, ovarian cancer mortality remai

172 rial to demonstrate a survival advantage for combination chemotherapy over cisplatin alone in advance

173 , surgical techniques, radiation therapy and combination chemotherapy over the past decades.

174 iver metastases in 2009 and 2010, palliative combination chemotherapy (oxaliplatin plus capecitabine)

175 with 9 of 27 (33%) treated with conventional combination chemotherapy (P = .036) despite similar tran

176 5-fluorouracil-doxorubicin-cyclophosphamide combination chemotherapy (P = 0.0048), particularly agai

177 We prospectively studied the use of combination chemotherapy plus cranial irradiation in new

178 ing standard combination chemotherapy versus combination chemotherapy plus flavopiridol is currently

179 ndomly assigned in nine trials that compared combination chemotherapy plus tamoxifen with tamoxifen a

180 cted a randomized trial to determine whether combination chemotherapy plus thoracic radiotherapy is s

181 This combination chemotherapy previously showed synergistic p

182 survival during a second round of intensive combination chemotherapy (probability of survival: 6-BG/

183 Combination chemotherapy produces a significant decrease

184 PAC combination chemotherapy produces response rates in the

185 w indicate that the addition of rituximab to combination chemotherapy prolongs progression-free and o

186 Compared with patients receiving combination chemotherapy protocols, those treated with s

187 f 65 or considered to be poor candidates for combination chemotherapy received docetaxel 36 mg/m2 wee

188 e effective and less toxic than the standard combination chemotherapy regimen ABV for treatment of AI

189 Combination chemotherapy regimen incorporating CD20 anti

190 totoxic agents, such as the recent promising combination chemotherapy regimen of folinic acid (leucov

191 apy can safely be eliminated from front-line combination chemotherapy regimens for advanced Hodgkin's

192 orticoid treatment, one of the components of combination chemotherapy regimens for lymphoma.

193 ts with high-risk metastatic disease receive combination chemotherapy regimens from the start.

194 rials of comparative standard platinum-based combination chemotherapy regimens have demonstrated infe

195 The use of pediatric intensive combination chemotherapy regimens in adolescents and you

196 Glucocorticoids are critical components of combination chemotherapy regimens in pediatric acute lym

197 Combination chemotherapy regimens including irinotecan a

198 le warrants further investigation, either in combination chemotherapy regimens or with targeted biolo

199 The rapid expansion in the use of improved combination chemotherapy regimens plus or minus biologic

200 boratory studies in the course of developing combination chemotherapy regimens that consist of topo I

201 algorithm to determine the emetogenicity of combination chemotherapy regimens was then designed by c

202 since the 1940s, and in the 1960s, effective combination chemotherapy regimens were introduced for an

203 Combination chemotherapy regimens were superior to singl

204 tinum drugs should be included in studies of combination chemotherapy regimens wherever possible.

205 inuously developing new anticancer drugs and combination chemotherapy regimens.

206 Retrospective studies suggest a benefit for combination chemotherapy regimens.

207 e optimal dose and schedule of paclitaxel in combination chemotherapy remain to be established.

208 Platinum and etoposide combination chemotherapy remains the standard of care in

209 Combination chemotherapy represents the standard-of-care

210 ddition of bevacizumab to fluorouracil-based combination chemotherapy results in statistically signif

211 When selecting combination chemotherapy salvage options, evaluation of

212 clinical studies that show the importance of combination chemotherapy, sanctuary-specific treatment,

213 After combination chemotherapy, six patients (three FLT3-ITD a

214 emale; age range, 12-42 y) were treated with combination chemotherapy (standard U.K. protocol) and (1

215 We compared sequential and combination chemotherapy strategies in patients with unp

216 ilable, including single-agent chemotherapy, combination chemotherapy strategies, radiotherapy, the i

217 nucleoside analogs plus alkylator agents, or combination chemotherapies, such as CHOP (cyclophosphami

218 le potential signaling targets for designing combination chemotherapies that could inhibit the synerg

219 opportunities for enhanced lymphoid-specific combination chemotherapies that have the potential to ov

220 o carefully evaluate the clinical effects of combination chemotherapies that incorporate antiangiogen

221 majority of patients (80%) were treated with combination chemotherapy that included an anthracycline,

222 10), patients received 44 weeks of identical combination chemotherapy that included high-dose methotr

223 This strategy should be compared with combination chemotherapy, the current standard of care.

224 Despite advances in combination chemotherapy, the overall survival for child

225 al chemoimmunotherapy included two cycles of combination chemotherapy, then an intradermal lower abdo

226 The relative value of gemcitabine-based combination chemotherapy therapy and prolonged infusions

227 We extend our approach of combination chemotherapy through a single prodrug entity

228 The ability of combination chemotherapy to cure acute childhood leukemi

229 Such a compound may be useful in novel combination chemotherapy to enhance the efficacy of alky

230 rapy, but it is being increasingly used with combination chemotherapy to improve the objective respon

231 t EZH2 phosphorylation should be included in combination chemotherapy to increase therapeutic index.

232 ible, HIV-1-infected patients should receive combination chemotherapy to minimize the emergence of re

233 CLC), shifting treatment from platinum-based combination chemotherapy to molecularly tailored therapy

234 The addition of combination chemotherapy to standard radiation therapy h

235 al appears to be improved by the addition of combination chemotherapy to tamoxifen.

236 Combination chemotherapy trials do not demonstrate a con

237 rivatives, as well as older single-agent and combination chemotherapy trials.

238 These findings suggest that combination chemotherapy used to treat children with ALL

239 y, and those who have high-risk disease with combination chemotherapy using etoposide, methotrexate a

240 Combination chemotherapy using paclitaxel with a platinu

241 recommend induction therapy with multi-agent combination chemotherapies (usually selected from bortez

242 esults, a phase III trial comparing standard combination chemotherapy versus combination chemotherapy

243 We compared the efficacy of combination chemotherapy versus single-agent therapy in

244 osed between 2002 and 2007, bevacizumab with combination chemotherapy was associated with improved ov

245 The addition of bevacizumab to cytotoxic combination chemotherapy was associated with small impro

246 Combination chemotherapy was initiated, and the cutaneou

247 initial complete response after risk-adapted combination chemotherapy were randomized to receive LD-I

248 ic colorectal cancer previously treated with combination chemotherapy were randomly assigned 1:1 to r

249 Initial cisplatin (CIS) combination chemotherapy will cure 70% of patients with

250 Combination chemotherapy with bevacizumab and erlotinib

251 Combination chemotherapy with bevacizumab, versus combin

252 Combination chemotherapy with CP significantly improves

253 The addition of rituximab to combination chemotherapy with cyclophosphamide, doxorubi

254 troviral therapy (HAART) alone to HAART with combination chemotherapy with doxorubicin, bleomycin and

255 Combination chemotherapy with gemcitabine, carboplatin,

256 Combination chemotherapy with HDPEB significantly improv

257 seful in designing future clinical trials of combination chemotherapy with l-OddC and CPT analogs wit

258 ingle-agent cisplatin (70 mg/m2 on day 1) or combination chemotherapy with methotrexate (30 mg/m2 on

259 andomized intergroup trial demonstrated that combination chemotherapy with methotrexate, vinblastine,

260 e III North American Intergroup E2496 Trial (Combination Chemotherapy With or Without Radiation Thera

261 of multimodality approaches, often including combination chemotherapy with or without radiation thera

262 amples from 1,282 patients enrolled onto the Combination Chemotherapy With or Without Trastuzumab in

263 Central Cancer Treatment Group NCCTG N9831 (Combination Chemotherapy With or Without Trastuzumab in

264 eplication-competent vectors was superior to combination chemotherapy with paclitaxel and carboplatin

265 Combination chemotherapy with purine analogues is showin

266 dependency to optimize the effectiveness of combination chemotherapy with Topo I and Topo II inhibit

267 Combination chemotherapy with VBL and MTX appears to con

268 Extensive-stage disease should be managed by combination chemotherapy, with a regimen such as etoposi

269 e treatment approach for many years has used combination chemotherapy, with usually an anthracycline

270 nation chemotherapy with bevacizumab, versus combination chemotherapy without bevacizumab, was associ

271 cancer (CRC) and who receive up-front modern combination chemotherapy without prophylactic surgery.

272 Combination chemotherapy yields a response rate of 24% a